Final-Program-ATS-2023-AP.vp

294

TUESDAY • MAY 23

3:39 A Pilot Study of Diagnostic Value of Sentinel-10 Liquid Biopsy Assay for the Detection of Malignancy in Pleural Fluid/ J. Lenka, Tucson, AZ 3:51 Use of Pleural Fluid Cell Free Deoxyribonucleic Acid (DNA) in Malignant Pleural Effusions/ M. Hagner, Iowa City, IA 4:03 Variations in the Metabolomic Profile Following Thoracic Surgery With Curative Intent in Lung Cancer. Preliminary Results From a Longitudinal Prospective Study (Promoter)/ L. Seijo, Madrid, Spain BASIC • CLINICAL • TRANSLATIONAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION C101 IMPACT OF BIOLOGICS ON ASTHMA OUTCOMES 2:15 p.m. - 4:15 p.m. Walter E. Washington Convention Center Room 103 A-B (Street Level) Viewing 2:15-3:00 Summaries/Discussion 3:00-4:15 Chairing: L. Eggert, MD, Stanford, CA P. Akuthota, MD, ATSF, La Jolla, CA R.P. Ramonell, MD, Pittsburgh, PA 201 Tezepelumab Efficacy by SNOT-22 Domain Scores in Patients With Severe, Uncontrolled Asthma and Comorbid Nasal Polyps in the Phase 3 Navigator Study/ J.D. Spahn, Wilmington, DE 202 Characteristics of Biological Treatment Failure in Patients With Severe Eosinophilic Asthma/ E. Zehr, Aurora, CO 203 Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years/ G. Brusselle, Ghent, Belgium 204 Baseline Predictors of an Enhanced Response to Tezepelumab Treatment Versus Placebo: Results From the Phase 3 NAVIGATOR Study/ A. Menzies-Gow, London, United Kingdom 205 Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults With Severe Asthma: Results From the DESTINATION Study/ A. Menzies-Gow, London, United Kingdom 206 Dupilumab Improved Long-term Lung Function in Children Aged 6 to 11 Years With Moderate-to-Severe Asthma: Liberty Asthma Excursion/ L.B. Bacharier, Nashville, TN

3:27 Arousal Intensity Predicts Incident Dementia in Sleep Apnea: The Multiethnic Study of Atherosclerosis (MESA)/ G.P. Labarca, Boston, MA 3:39 Polysomnography-derived Hypoxemic Markers Associated With Pulmonary Hypertension in Obstructive Sleep Apnea/ S. Hassan, Burlington, VT 3:51 Polysomnographic Determinants of Nondipping Blood Pressure Pattern in Obstructive Sleep Apnea/ L. Pinilla Latorre, Lleida, Spain Featured Speaker: 4:03 Prognostic in Obstructive Sleep Apnea/ H.K. Yaggi, New Haven, CT

BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

C99

ADVANCES IN BIOMARKERS ACROSS THE LUNG CANCER CONTINUUM

2:15 p.m. - 4:15 p.m.

Walter E. Washington Convention Center Room 202 B (Level 2)

Chairing: A. Vachani, MD, MS, Philadelphia, PA N.T. Tanner, MD, MSCR, Charleston, SC Oral Presentations: 2:15 Improved Lung Cancer Detection in Setting of Underutilized CT Screening: Combination of a Lung Cancer Biomarker With Clinical Risk Assessment/ P.B. Bach, Baltimore, MD 2:27 Cell-free Tumor DNA in Blood and Bronchoalveolar Lavage (BAL) as a Biomarker in Non-Small Cell Lung Cancer/ K. Zhang, Hamilton, Canada 2:39 Prospective Evaluation of cfDNA Fragmentomes for Lung Cancer Detection/ P.J. Mazzone, Cleveland, OH 2:51 Mortality Benefit of a Blood-based Biomarker Panel for Lung Cancer Based on the PLCO Cohort/ E. Ostrin, Houston, TX 3:03 The Role of Syndecan 4 and Cyfra 21.1 in the Diagnosis of Non-small Cell Lung Cancer/ A. Santoso, Makassar, Indonesia 3:15 Assessment of an Integrated Classifier’s Ability to Distinguish Benign From Malignant Nodules: Subgroup Analysis of the Oracle Registry/ K.J. Long, Charleston, SC 3:27 Shifting the Intervention Probability Curve for Lung Cancer Diagnosis Following Biomarker Implementation: A Novel Clinical Endpoint for Biomarker Clinical Trials/ M.N. Kammer, Nashville, TN

ATS 2023 • Washington, DC